MHRA chief urges caution over trial data release
This article was originally published in Scrip
Executive Summary
Publishing full clinical study reports may not be the best way of increasing transparency of clinical trial data, mainly because of the time and cost involved in redacting personal data, according to Sir Kent Woods, head of the UK regulatory agency, the MHRA.